The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
28 Jun 2022
Cancer patient symptom and physical function reporting by caregivers used as pre...
Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, ...
Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes ( Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, USA )
21 Jun 2022
War in Ukraine: Global cancer aid to support refugees
Dr Horia Vulpe , Dr Ruslan Baltaga
War in Ukraine: Global cancer aid to support refugees ( Dr Horia Vulpe , Dr Ruslan Baltaga )
21 Jun 2022
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphom...
Dr Carol Moreno - University of Barcelona, Barcelona, Spain
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )
21 Jun 2022
ASCO and WHO to collaborate on quality indicators for cancer facilities
Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland
ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )
14 Jun 2022
Efficacy and safety of ARI0002H, a BCMA-directed CAR-T cell therapy with fractio...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
Efficacy and safety of ARI0002H, a BCMA-directed CAR-T cell therapy with fractionated initial therapy and booster dose in RRMM ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
Safety and efficacy of the bispecific antibody talquetamab in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
Safety and efficacy of the bispecific antibody talquetamab in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022
Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive AL...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Jun 2022
Subcutaneous isatuximab administration by an on-body delivery system in combinat...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
Subcutaneous isatuximab administration by an on-body delivery system in combination with pomalidomide-dexamethasone in RRMM ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )
13 Jun 2022
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )
13 Jun 2022
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )
13 Jun 2022
A single dose of ctx001 shows promising efficacy and safety for TDT and severe S...
Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy
A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD ( Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy )
13 Jun 2022

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation